AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26718897 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group) including distribution of IFA to mothers of anemic children without education and counseling support.
Number of subjects: 60
Study 24077193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical epidural injections with lidocaine 0.5% preservative-free, 5 mL (Group I)
Number of subjects: 120
Study 24077193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical epidural injections with 0.5% preservative-free lidocaine mixed with 1 mL or 6 mg of non-particulate betamethasone (Group II)
Number of subjects: 120
Study 24077193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical epidural injections with lidocaine 0.5% preservative-free (Group I)
Number of subjects: 120
Study 21180682 — intervention group
Group type: EXPERIMENTAL
Intervention: Inion GTR Biodegradable Membrane System barrier without any graft
Number of subjects: 10
Study 21180682 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss (100% loosely packed granular)
Number of subjects: 10
Study 19067478 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led sex education
Number of subjects: 9000
Study 19067478 — intervention group
Group type: COMPARATOR
Intervention: Control (teacher-led sex education)
Number of subjects: 9000
Study 21029654 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 multislice CT at 80 kV
Number of subjects: 120
Study 21029654 — intervention group
Group type: COMPARATOR
Intervention: 64 multislice CT at 100 kV
Number of subjects: 120
Study 21029654 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography with Doppler
Number of subjects: 120
Study 15579575 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin A, C, and E regimen, supplemented orally for 2 months
Number of subjects: 18
Study 12450708 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3 ligand (20 microg/kg, maximum 1500 microg) administered SQ every day for 1 week
Number of subjects: 40
Study 12450708 — intervention group
Group type: COMPARATOR
Intervention: Flt3 ligand (placebo control)
Number of subjects: 40
Study 9883957 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie management
Number of subjects: 0
Study 9883957 — intervention group
Group type: COMPARATOR
Intervention: Non-specific back massage and general back care advice (Control)
Number of subjects: 0
Study 7976313 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B tympanogram
Number of subjects: 370
Study 7976313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometry
Number of subjects: 370
Study 2657199 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% with epinephrine 0.5% plus guanethidine 3%
Number of subjects: 0
Study 2657199 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 0.5% plus guanethidine 3%
Number of subjects: 0
Study 2657199 — intervention group
Group type: COMPARATOR
Intervention: Timolol alone
Number of subjects: 0
Study 2657199 — intervention group
Group type: COMPARATOR
Intervention: Other glaucoma drugs
Number of subjects: 0
Study 11961621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH)
Number of subjects: 48
Study 29574905 — intervention group
Group type: EXPERIMENTAL
Intervention: Play-based psychosocial intervention
Number of subjects: 14
Study 27502284 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Health Awareness program
Number of subjects: 370
Study 27502284 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study 25336703 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery only
Number of subjects: 637
Study 25336703 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 637
Study 25336703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin ≤ 850 mg
Number of subjects: 637
Study 22424162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 182
Study 22424162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study 20545874 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at 2 Hz-burst
Number of subjects: 45
Study 20545874 — intervention group
Group type: COMPARATOR
Intervention: Control (no electro-acupuncture)
Number of subjects: 45
Study 20545874 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 45
Study 18569006 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g NS day(‐1) (high dose, HD)
Number of subjects: 177
Study 18569006 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g NS day(‐1) (low dose, LD)
Number of subjects: 177
Study 18569006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 177
Study 16222401 — intervention group
Group type: EXPERIMENTAL
Intervention: D-hormone serum concentrations (high)
Number of subjects: 380
Study 16222401 — intervention group
Group type: COMPARATOR
Intervention: D-hormone serum concentrations (low)
Number of subjects: 380
Study 16222401 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake >= 512 mg/day
Number of subjects: 380
Study 16222401 — intervention group
Group type: COMPARATOR
Intervention: Calcium intake < 512 mg/day
Number of subjects: 380
Study 16222401 — intervention group
Group type: EXPERIMENTAL
Intervention: D-hormone serum concentrations
Number of subjects: 380
Study 16222401 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcidiol serum levels
Number of subjects: 380
Study 12610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic Neuropathy Symptom (DNS) score
Number of subjects: 69
Study 12610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic Neuropathy Examination (DNE) score
Number of subjects: 69
Study 12610024 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 69
Study 10496143 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg) administered at 13:00 hr for 5 consecutive days during the late follicular and early luteal phases of the menstrual cycle.
Number of subjects: 0
Study 10496143 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 0
Study 7795515 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg atracurium
Number of subjects: 40
Study 7795515 — intervention group
Group type: COMPARATOR
Intervention: 0.07 mg/kg vecuronium
Number of subjects: 40
Study 2385209 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ASS daily
Number of subjects: 20
Study 2385209 — intervention group
Group type: COMPARATOR
Intervention: 300 mg ASS daily
Number of subjects: 20
Study 6994760 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 6994760 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study 29974308 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exclusion measure (experimental group)
Number of subjects: 60
Study 29974308 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no self-exclusion)
Number of subjects: 60
Study 29953014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashwagandha extract (daily supplement for 42 days)
Number of subjects: 0
Study 29953014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily supplement for 42 days)
Number of subjects: 0
Study 27590106 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Dexamethasone (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Number of subjects: 46
Study 27590106 — intervention group
Group type: COMPARATOR
Intervention: Topical Tacrolimus (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Number of subjects: 46
Study 27590106 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Dexamethasone
Number of subjects: 46
Study 27590106 — intervention group
Group type: COMPARATOR
Intervention: Topical Tacrolimus
Number of subjects: 46
Study 24946627 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group
Number of subjects: 145
Study 24946627 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 145
Study 24946627 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion group
Number of subjects: 145
Study 23013731 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutation
Number of subjects: 150
Study 23013731 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutation
Number of subjects: 150
Study 23013731 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrioid tumors
Number of subjects: 150
Study 23013731 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant mixed Mullerian tumors
Number of subjects: 150
Study 23013731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade endometrioid cancers
Number of subjects: 150
Study 20047770 — intervention group
Group type: COMPARATOR
Intervention: Usual Quality Improvement Program (UQIP)
Number of subjects: 2495
Study 20047770 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Quality Improvement Program (AQIP)
Number of subjects: 2495
Study 16936007 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 240
Study 16936007 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide + Nicorandil
Number of subjects: 240
Study 16936007 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 240
Study 16779202 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHENA DSS with point-of-care feedback
Number of subjects: 0
Study 12117085 — intervention group
Group type: EXPERIMENTAL
Intervention: T/APAP 75/650 mg (2 tablets)
Number of subjects: 200
Study 12117085 — intervention group
Group type: EXPERIMENTAL
Intervention: HC/APAP (1 tablet)
Number of subjects: 200
Study 12117085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12117085 — intervention group
Group type: EXPERIMENTAL
Intervention: T/APAP 75/650 mg (1 tablet)
Number of subjects: 200
Study 11332162 — intervention group
Group type: EXPERIMENTAL
Intervention: Colicky infants (HRV analysis)
Number of subjects: 12
Study 11332162 — intervention group
Group type: COMPARATOR
Intervention: Control infants (HRV analysis)
Number of subjects: 12
Study 11332162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HRV analysis)
Number of subjects: 12
Study 10387366 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7518766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous or intramuscular ceftriaxone 50 mg/kg/day for 2 days followed by oral cefetamet pivoxil 20 mg/kg/day in 2 divided doses to complete 7 days of treatment (arm A)
Number of subjects: 118
Study 7518766 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 50 mg/kg/day for 1 day followed by 6 days' treatment with cefetamet pivoxil 20 mg/kg/day (arm B)
Number of subjects: 118
Study 2923962 — intervention group
Group type: COMPARATOR
Intervention: 4 x 10 mg test tablets, 1 x 40 mg test tablet, 4 x 10 mg Inderal tablets, 40 mg of propranolol HCl in solution (Study I)
Number of subjects: 48
Study 2923962 — intervention group
Group type: COMPARATOR
Intervention: 1 x 80 mg test tablet, 1 x 80 mg Inderal tablet, 80 mg of propranolol HCl in solution (Study II)
Number of subjects: 48
Study 824929 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 74.917 aerosol
Number of subjects: 10
Study 824929 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate powder
Number of subjects: 10
Study 824929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31736394 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin's pessary and vaginal micronized progesterone (Group A, n=60)
Number of subjects: 120
Study 31736394 — intervention group
Group type: COMPARATOR
Intervention: Vaginal micronized progesterone only (Group B, n=60)
Number of subjects: 120
Study 31212044 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific balance rehabilitation exercises
Number of subjects: 150
Study 31212044 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient therapy
Number of subjects: 150
Study 31212044 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a walking aid
Number of subjects: 150
Study 31212044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline BBS score
Number of subjects: 150
Study 31212044 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific treatment
Number of subjects: 150
Study 31212044 — intervention group
Group type: EXPERIMENTAL
Intervention: pMS vs. relapsing-remitting MS
Number of subjects: 150
Study 31593484 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil bolus 400 mg/m2 on day 1, fluorouracil infusion 2,400 mg/m2 for 46 hours)
Number of subjects: 321
Study 31593484 — intervention group
Group type: COMPARATOR
Intervention: FL (fluorouracil 380 mg/m2 and leucovorin 20 mg/m2)
Number of subjects: 321
Study 31593484 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 321
Study 31593484 — intervention group
Group type: COMPARATOR
Intervention: FL
Number of subjects: 321
Study 28486344 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic diseases
Number of subjects: 516
Study 28486344 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 516
Study 25218876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (100 mL before each dialysis session)
Number of subjects: 24
Study 25218876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (1,050 mg daily)
Number of subjects: 24
Study 24106787 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured transition program (multidisciplinary, complex intervention)
Number of subjects: 188
Study 24106787 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 188
Study 24106787 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured transition program
Number of subjects: 188
Study 21793817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraditional practice (problems presented in a nontraditional format, e.g., 17 = 9 + 8)
Number of subjects: 90
Study 21793817 — intervention group
Group type: COMPARATOR
Intervention: Traditional practice (problems presented in the traditional 'operations on left side' format, e.g., 9 + 8 = 17)
Number of subjects: 90
Study 21793817 — intervention group
Group type: COMPARATOR
Intervention: No extra practice
Number of subjects: 90
Study 19262008 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 21
Study 19262008 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 21
Study 16738028 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-anchoring
Number of subjects: 0
Study 16738028 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-stereotyping
Number of subjects: 0
Study 15305956 — intervention group
Group type: EXPERIMENTAL
Intervention: Short nitroglycerine test (15 minutes passive phase + 400 microg sublingual nitroglycerin for 15 minutes)
Number of subjects: 128
Study 15305956 — intervention group
Group type: COMPARATOR
Intervention: Conventional isoproterenol protocol (30 minutes passive phase + 20 minutes drug-challenge phase)
Number of subjects: 128
Study 15305956 — intervention group
Group type: EXPERIMENTAL
Intervention: Short nitroglycerine test
Number of subjects: 128
Study 15305956 — intervention group
Group type: COMPARATOR
Intervention: Conventional isoproterenol protocol
Number of subjects: 128
Study 11165450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active outreach with $5 per visit incentive (Condition 1)
Number of subjects: 163
Study 11165450 — intervention group
Group type: COMPARATOR
Intervention: Active outreach without monetary incentive (Condition 2)
Number of subjects: 163
Study 11165450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active outreach at study community site with $5 per visit incentive (Condition 3)
Number of subjects: 163
Study 9410508 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength and coordination training program
Number of subjects: 0
Study 9410508 — intervention group
Group type: COMPARATOR
Intervention: Light physical exercise (Control)
Number of subjects: 0
Study 8437633 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A (Centoxin), a human anti-endotoxin monoclonal IgM antibody
Number of subjects: 0
Study 8437633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3728506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 179
Study 3728506 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 179
Study 3728506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin with liver disease
Number of subjects: 179
Study 3728506 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime with liver disease
Number of subjects: 179
Study 3728506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin without liver disease
Number of subjects: 179
Study 30376366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (2×60 minute supervised sessions per week)
Number of subjects: 28
Study 30376366 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study 30376366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28
Study 30376366 — intervention group
Group type: COMPARATOR
Intervention: Usual care and Exercise training
Number of subjects: 28
Study 30157880 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra, self-administered daily by subcutaneous injection over 8 weeks
Number of subjects: 64
Study 30157880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27125363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus lamivudine (dual-therapy)
Number of subjects: 239
Study 27125363 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Number of subjects: 239
Study 27125363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus lamivudine (dual-therapy) with discontinuation of tenofovir-DF
Number of subjects: 239
Study 27125363 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir plus two NRTIs (triple-therapy) with discontinuation of abacavir
Number of subjects: 239
Study 27125363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus lamivudine (dual-therapy) and Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Number of subjects: 239
Study 24915904 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance based case management programme
Number of subjects: 0
Study 24915904 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study 23075176 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone continued for 32 weeks (group 1)
Number of subjects: 110
Study 23075176 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone for 16 weeks followed by placebo for 16 weeks (group 2)
Number of subjects: 110
Study 23075176 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 32 weeks (group 3)
Number of subjects: 110
Study 20398185 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced blood sampling schedule for children
Number of subjects: 152
Study 20398185 — intervention group
Group type: COMPARATOR
Intervention: Standard blood sampling schedule
Number of subjects: 152
Study 20398185 — intervention group
Group type: EXPERIMENTAL
Intervention: PK measurements for dose tailoring of FVIII
Number of subjects: 152
Study 16835823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Training (IT)
Number of subjects: 16
Study 16835823 — intervention group
Group type: COMPARATOR
Intervention: Normal Training (NT)
Number of subjects: 16
Study 16835823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 15923803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy (MT)
Number of subjects: 6
Study 15923803 — intervention group
Group type: COMPARATOR
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 6
Study 12884068 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 239
Study 12884068 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 239
Study 10475187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusions of L-arginine
Number of subjects: 0
Study 10475187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusions of sodium nitroprusside
Number of subjects: 0
Study 8864503 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 0
Study 8864503 — intervention group
Group type: EXPERIMENTAL
Intervention: Infra-red thermography
Number of subjects: 0
Study 1926024 — intervention group
Group type: EXPERIMENTAL
Intervention: Care of a respiratory health worker
Number of subjects: 152
Study 1926024 — intervention group
Group type: COMPARATOR
Intervention: Normal services provided by the outpatient department
Number of subjects: 152
Study 6353842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens implantation
Number of subjects: 61
Study 6353842 — intervention group
Group type: COMPARATOR
Intervention: Extended-wear contact lenses
Number of subjects: 61
Study 4002834 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 18
Study 31987545 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with the custom-made visual feedback device
Number of subjects: 34
Study 31987545 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 34
Study 29761274 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure (8 mmHg) with deep-block (post-tetanic count 1-2)
Number of subjects: 131
Study 29761274 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intra-abdominal pressure (12 mmHg) with deep-block
Number of subjects: 131
Study 29761274 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intra-abdominal pressure (12 mmHg) with moderate-block (train-of-four count 1-2)
Number of subjects: 131
Study 29761274 — intervention group
Group type: COMPARATOR
Intervention: Low intra-abdominal pressure (8 mmHg)
Number of subjects: 131
Study 29761274 — intervention group
Group type: COMPARATOR
Intervention: Standard intra-abdominal pressure (12 mmHg)
Number of subjects: 131
Study 27633636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-led rehabilitation intervention for stroke patients, details on dosage and duration not specified.
Number of subjects: 0